FDA Clears MagVenture's MagVita TMS Therapy System
The FDA has cleared MagVenture's MagVita TMS Therapy system for use in treating adults with major depressive disorder who have failed to improve with antidepressant medication.
The noninvasive system works by stimulating neural tissue in the part of the brain implicated in patients suffering from the disorder. It was cleared for use in the EU in 2011.
Kerry Rome, MagVenture’s vice president of sales, says the system will drive down the cost psychotherapy, as there are no per-use fees or costly disposable components involved.
MagVenture specializes in noninvasive magnetic stimulation systems for depression treatment as well as research in the areas of neurophysiology, neurology, cognitive neuroscience, rehabilitation, and psychiatry. The MagVita system is manufactured by MagVenture’s sister company Tonica in Denmark. — Michael Cipriano